Polylactide Nanoparticles As a Biodegradable Vaccine Adjuvant: A Study on Safety, Protective Immunity and Efficacy Against Human Leishmaniasis Caused by Leishmania Major

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2022 Dec 23

PMID 36557812

Authors

Sana Ayari-Riabi

Noureddine Ben Khalaf

Balkiss Bouhaouala-Zahar

Bernard Verrier

Thomas Trimaille

Zakaria Benlasfar

Mehdi Chenik

Mohamed ElAyeb

Affiliations

Soon will be listed here.

Abstract

Leishmaniasis is the 3rd most challenging vector-borne disease after malaria and lymphatic filariasis. Currently, no vaccine candidate is approved or marketed against leishmaniasis due to difficulties in eliciting broad immune responses when using sub-unit vaccines. The aim of this work was the design of a particulate sub-unit vaccine for vaccination against leishmaniasis. The poly (D,L-lactide) nanoparticles (PLA-NPs) were developed in order to efficiently adsorb a recombinant histone H2B H2B) and to boost its immunogenicity. Firstly, a study was focused on the production of well-formed nanoparticles by the nanoprecipitation method without using a surfactant and on the antigen adsorption process under mild conditions. The set-up preparation method permitted to obtain H2B-adsorbed nanoparticles H2B/PLA (adsorption capacity of about 2.8% (/)) with a narrow size distribution (287 nm) and a positive zeta potential (30.9 mV). Secondly, an in vitro release assay performed at 37 °C, pH 7.4, showed a continuous release of the adsorbed H2B for almost 21 days (30%) from day 7. The immune response of H2B/PLA was investigated and compared to H2B + CpG7909 as a standard adjuvant. The humoral response intensity (IgG) was substantially similar between both formulations. Interestingly, when challenged with the standard parasite strain (GLC94) isolated from a human lesion of cutaneous leishmaniasis, mice showed a significant reduction in footpad swelling compared to unvaccinated ones, and no deaths occurred until week 17th. Taken together, these results demonstrate that PLA-NPs represent a stable, cost-effective delivery system adjuvant for use in vaccination against leishmaniasis.

Citing Articles

From classical approaches to new developments in genetic engineering of live attenuated vaccine against cutaneous leishmaniasis: potential and immunization.

Rooholamini Z, Dianat-Moghadam H, Esmaeilifallah M, Khanahmad H Front Public Health. 2024; 12:1382996.

PMID: 39035184 PMC: 11257927. DOI: 10.3389/fpubh.2024.1382996.

A New Strategy for Mapping Epitopes of LACK and PEPCK Proteins of Specific for Major Histocompatibility Complex Class I.

Ferreira-Sena E, Hardoim D, Cardoso F, dEscoffier L, Soares I, Carvalho J Int J Mol Sci. 2023; 24(6).

PMID: 36983046 PMC: 10054446. DOI: 10.3390/ijms24065972.

Polylactide-Based Materials: Synthesis and Biomedical Applications.

Brzezinski M, Basko M Molecules. 2023; 28(3).

PMID: 36771051 PMC: 9920252. DOI: 10.3390/molecules28031386.

References

Gheibi Hayat S, Darroudi M . Nanovaccine: A novel approach in immunization. J Cell Physiol. 2019; 234(8):12530-12536. DOI: 10.1002/jcp.28120. View

Choudhury R, Das P, De T, Chakraborti T . 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity. Immunobiology. 2012; 218(1):114-26. DOI: 10.1016/j.imbio.2012.02.008. View

Venkataprasad N, Coombes A, Singh M, Rohde M, Wilkinson K, Hudecz F . Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers. Vaccine. 1999; 17(15-16):1814-9. DOI: 10.1016/s0264-410x(98)00372-7. View

Ayari-Riabi S, Trimaille T, Mabrouk K, Bertin D, Gigmes D, Benlasfar Z . Venom conjugated polylactide applied as biocompatible material for passive and active immunotherapy against scorpion envenomation. Vaccine. 2016; 34(15):1810-5. DOI: 10.1016/j.vaccine.2016.02.030. View

Liew F, ODonnell C . Immunology of leishmaniasis. Adv Parasitol. 1993; 32:161-259. DOI: 10.1016/s0065-308x(08)60208-0. View

Pace D . Leishmaniasis. J Infect. 2014; 69 Suppl 1:S10-8. DOI: 10.1016/j.jinf.2014.07.016. View

Palma E, Cho M . Improved systemic pharmacokinetics, biodistribution, and antitumor activity of CpG oligodeoxynucleotides complexed to endogenous antibodies in vivo. J Control Release. 2007; 120(1-2):95-103. PMC: 1976275. DOI: 10.1016/j.jconrel.2007.03.016. View

Joshi V, Geary S, Salem A . Biodegradable particles as vaccine antigen delivery systems for stimulating cellular immune responses. Hum Vaccin Immunother. 2013; 9(12):2584-90. PMC: 4162053. DOI: 10.4161/hv.26136. View

Armijos R, Weigel M, Calvopina M, Hidalgo A, Cevallos W, Correa J . Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine. 2004; 22(9-10):1320-6. DOI: 10.1016/j.vaccine.2003.06.002. View

10.

Margaroni M, Agallou M, Kontonikola K, Karidi K, Kammona O, Kiparissides C . PLGA nanoparticles modified with a TNFα mimicking peptide, soluble Leishmania antigens and MPLA induce T cell priming in vitro via dendritic cell functional differentiation. Eur J Pharm Biopharm. 2016; 105:18-31. DOI: 10.1016/j.ejpb.2016.05.018. View

11.

Lemery E, Briancon S, Chevalier Y, Oddos T, Gohier A, Boyron O . Surfactants have multi-fold effects on skin barrier function. Eur J Dermatol. 2015; 25(5):424-35. DOI: 10.1684/ejd.2015.2587. View

12.

Bennis I, Thys S, Filali H, De Brouwere V, Sahibi H, Boelaert M . Psychosocial impact of scars due to cutaneous leishmaniasis on high school students in Errachidia province, Morocco. Infect Dis Poverty. 2017; 6(1):46. PMC: 5383955. DOI: 10.1186/s40249-017-0267-5. View

13.

Soto M, Requena J, Quijada L, Perez M, Nieto C, Guzman F . Antigenicity of the Leishmania infantum histones H2B and H4 during canine viscerocutaneous leishmaniasis. Clin Exp Immunol. 1999; 115(2):342-9. PMC: 1905166. DOI: 10.1046/j.1365-2249.1999.00796.x. View

14.

Elfaki M, Khalil E, De Groot A, Musa A, Gutierrez A, Younis B . Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines. Hum Vaccin Immunother. 2012; 8(12):1769-74. PMC: 3656064. DOI: 10.4161/hv.21881. View

15.

Yasinzai M, Khan M, Nadhman A, Shahnaz G . Drug resistance in leishmaniasis: current drug-delivery systems and future perspectives. Future Med Chem. 2013; 5(15):1877-88. DOI: 10.4155/fmc.13.143. View

16.

Launois P, Conceicao-Silva F, Himmerlich H, Parra-Lopez C, Tacchini-Cottier F, Louis J . Setting in motion the immune mechanisms underlying genetically determined resistance and susceptibility to infection with Leishmania major. Parasite Immunol. 1998; 20(5):223-30. DOI: 10.1046/j.1365-3024.1998.00153.x. View

17.

Mallapragada S, Narasimhan B . Immunomodulatory biomaterials. Int J Pharm. 2008; 364(2):265-71. DOI: 10.1016/j.ijpharm.2008.06.030. View

18.

Katebi A, Varshochian R, Riazi-Rad F, Ganjalikhani-Hakemi M, Ajdary S . Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates Leishmania major-infected-macrophages activation. Biomed Pharmacother. 2021; 137:111276. DOI: 10.1016/j.biopha.2021.111276. View

19.

Moafi M, Rezvan H, Sherkat R, Taleban R . Vaccines Entered in Clinical Trials: A Review of Literature. Int J Prev Med. 2019; 10:95. PMC: 6592111. DOI: 10.4103/ijpvm.IJPVM_116_18. View

20.

Benhnini F, Chenik M, Laouini D, Louzir H, Cazenave P, Dellagi K . Comparative evaluation of two vaccine candidates against experimental leishmaniasis due to Leishmania major infection in four inbred mouse strains. Clin Vaccine Immunol. 2009; 16(11):1529-37. PMC: 2772381. DOI: 10.1128/CVI.00153-09. View